Peringkat dalam Saham
#20648
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Harga Saham
$0.517
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$125.14M
Perubahan (1 hari)
-0.58%
Perubahan (1 tahun)
47.71%
Perdagangan Vaxart, Inc. (VXRT)
Harga VXRT dengan kapitalisasi pasar B
Kapitalisasi pasar dari Vaxart, Inc.(VXRT)
Kapitalisasi Pasar: $125.14M
Per August 2026, Vaxart, Inc. memiliki kapitalisasi pasar sebesar $125.14M. Ini menjadikan Vaxart, Inc. sebagai perusahaan 20648th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Vaxart, Inc. dari 1981 hingga 2026
VXRT dibandingkan dengan 5 teratas stocks paling populer
| Harga VXRT |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.211T
|
+4,164,442.00%
|
|
|
|
|
$4.547T
|
+3,633,324.35%
|
|
|
|
|
$4.162T
|
+3,326,244.06%
|
|
|
|
|
$3.593T
|
+2,870,993.60%
|
|
|
|
|
$2.793T
|
+2,231,743.37%
|
